Skip to main content

Table 1 Zebrafish models of leukemia and other hematological disorders

From: Zebrafish as a model for leukemia and other hematopoietic disorders

Disease model

Gene

Expression

Latency

Penetrance

References

AML

Hs RUNX1-ETO

Ubiquitous

Embryonic

32–41%

[22]

Ubiquitous - inducible (hs)

Embryonic (induced)

NS

[43,44]

Hs MOZ/TIF2

Progenitor (spi1)

14–26 months

1%

[47]

Hs FLT3

Ubiquitous

Embryonic

NS

[49]

Hs NPMc +

Ubiquitous

Embryonic

NS

[51]

Mm Mycn

Ubiquitous - inducible (hs)

Embryonic (induced)

F0: 60% F2: 75%

[54]

Dr spi1 G242D

Endogenous - hypomorph

3 days

NS

[57]

Dr ddx18

Knockout

Embryonic

NS

[58]

ALL

Mm Myc

Lymphoid (rag2)

F0: 44–52 days F1: 32 days

F0: 5–6% F1: 100%

[2,34,59]

Lymphoid (rag2) - inducible (cre)

151 days

13%

[61]

Lymphoid (rag2) - inducible (cre/hs)

T-LBL: 120 days/T-ALL: 261 days

T-LBL: 81%/T-ALL: 100%

[62,63]

Hs MYC

Ubiquitous - inducible (4HT)

4–5 weeks (induced)

100%

[66,68]

Dr pten

Knockout

Embryonic

NS

[70,71]

Hs NOTCH1ic

Lymphoid (rag2)

5 months

44%

[73]

Hs ETV6-RUNX1

Ubiquitous

1 year

3%

[75]

Dr etv6-jak2a (ALL)

Ubiquitous/Progenitor (spi1)

Embryonic

30%/50%

[78]

MPD

Dr jak2a V581F

Ubiquitous

Embryonic

NS

[87]

Dr stat5 H298R/N714F

Ubiquitous

Embryonic

NS

[88]

Dr etv6-jak2a (CML)

Ubiquitous/Progenitor (spi1)

Embryonic

30%/50%

[78,89]

Hs kRAS G12D

Ubiquitous - inducible (hs + cre)

34 days (induced)

8%

[91]

Hs HRAS G12V

Endothelial (fli1)

Embryonic

NS

[92]

Hs NUP98-HOXA9

Progenitor (spi1) - inducible (hs + cre)

19–23 months

23%

[97]

Hs KIT D816V

Ubiquitous

3–30 months

48–52 %

[93]

MDS

Dr tet2

Knockout

2 years

NS

[95]

Dr hspa9b

Knockout

Embryonic

80%

[98]

  1. Hs: Homo sapiens; Mm: Mus musculus; Dr: Danio rerio; AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; MPD: myeloproliferative disease; MDS: myelodysplastic syndrome; NS: not specified; F0: founder; F1: first generation; F2: second generation; hs: heat shock; 4HT: 4-hydroxytamoxifen.